Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma
Article in Diagnostics (June 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Article in Diagnostics (June 2024)
Article in The Journal of Allergy and Clinical Immunology In Practice (May 2023)
Article in Antioxidants (February 2023)